CAMP — Camp4 Therapeutics Corp
Price · 2024-10-11 → 2026-08-21
466 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2024-10-11.
Performance
Technicals
Others in Healthcare
Measured signals that fired on CAMP
| date | signal | measured base rate |
|---|---|---|
| 2026-08-05 | Cluster buy: three or more insiders insider | +0.63% over 21 days · t = 1.84 · n = 3,050 not distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-21 | Schwab Andrew J. Director | Open-market sale | 32.0K | 4.50 | 144.1K |
| 2026-08-20 | Schwab Andrew J. Director | Open-market sale | 114.7K | 4.54 | 520.7K |
| 2026-08-19 | Schwab Andrew J. Director | Open-market sale | 45.1K | 4.76 | 214.9K |
| 2026-08-19 | Tardiff Daniel Chief Scientific Officer | Open-market sale | 1.7K | 4.76 | 8.3K |
| 2026-08-03 | Young Richard A Director | Open-market purchase | 16.4K | 1.65 | 27.0K |
| 2026-08-03 | Maricich Yuri Chief Medical Officer | Open-market purchase | 6.6K | 1.65 | 10.8K |
| 2026-08-03 | Gold Kelly Chief Financial Officer | Open-market purchase | 6.6K | 1.65 | 10.8K |
| 2026-08-03 | Mandel-Brehm Josh Chief Executive Officer | Open-market purchase | 6.6K | 1.65 | 10.8K |
| 2025-09-11 | PARMAR KUSH | Open-market purchase | 2.9M | 1.53 | 4.5M |
| 2025-09-11 | Schwab Andrew J. Director | Grant or award | 2.9M | 1.53 | 4.5M |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| JANUS HENDERSON GROUP PLC | 27.9M | 6.3M |
| 5AM Venture Management, LLC | 25.9M | 5.9M |
| FMR LLC | 21.8M | 4.9M |
| Vivo Capital, LLC | 18.7M | 4.2M |
| Balyasny Asset Management L.P. | 11.6M | 2.6M |
| ENAVATE SCIENCES GP, LLC | 9.7M | 2.2M |
| a16z Capital Management, L.L.C. | 9.4M | 2.1M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 8.6M | 2.0M |
| Trails Edge Capital Partners, LP | 8.6M | 1.9M |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.8M | 1.5M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Camp4 Therapeutics GAAP EPS of -$0.58 misses by $0.37 · 2026-08-13
- Camp4 Therapeutics Corp (CAMP) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about CAMP
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →